Rehman S U, Januzzi J L
Department of Medicine and Division of Cardiology, Harvard Medical School and Massachusetts, General Hospital, Boston, MA 02114, USA.
Panminerva Med. 2008 Jun;50(2):139-51.
Natriuretic peptide testing in the form of B-type natriuretic peptide (BNP) or NT-proBNP measurement has revolutionized modern heart failure (HF) diagnostics for those patients with acute symptoms, and promises to have similarly profound effects not only for the earlier recognition of those with HF, but also for the therapy of patients across the entire spectrum of HF. Future efforts are necessary to better understand the complex biology of the natriuretic peptides, to further optimize use of the assays for their measurement, and to gain clarity regarding the appropriate venue for their measurement. The ultimate goal is to recognize more readily and treat the syndrome that is HF, in order to reduce the considerable morbidity and mortality among those so afflicted.
以B型利钠肽（BNP）或N末端B型利钠肽原（NT-proBNP）测量形式进行的利钠肽检测，彻底改变了对有急性症状患者的现代心力衰竭（HF）诊断方法，不仅有望对HF患者的早期识别产生同样深远的影响，而且对整个HF谱系患者的治疗也有类似作用。未来有必要进一步努力，以更好地理解利钠肽的复杂生物学特性，进一步优化其检测方法的使用，并明确其测量的合适场所。最终目标是更易于识别并治疗HF综合征，以降低此类患者中相当高的发病率和死亡率。
